Electrodiagnosis

InventHelp Inventor Develops a Modified ECG/EKG Electrode Design (TPA-3014)

Retrieved on: 
Wednesday, December 23, 2020
Branches of biology, Medicine, Clinical medicine, Cardiac electrophysiology, Electrodiagnosis, Electrophysiology, Electrocardiography, Electrode

The invention fulfills the need for a modified ECG/EKG electrode.

Key Points: 
  • The invention fulfills the need for a modified ECG/EKG electrode.
  • The design offers added comfort, and would be safe and easy to use.
  • The use of this modified electrode could provide peace of mind to patients and medical professionals.
  • The original design was submitted to the Tampa sales office of InventHelp.

Assure Holdings Announces Results of Annual General and Special Meeting of Shareholders

Retrieved on: 
Friday, December 11, 2020
Medical specialties, Clinical medicine, Medicine, Anesthesia, Electrodiagnosis, Electroencephalography, Intraoperative neurophysiological monitoring, Medical monitoring, Orthopedic surgery

Both the Amended Option Plan and the Equity Incentive Plan remain subject to the approval of the TSX Venture Exchange.

Key Points: 
  • Both the Amended Option Plan and the Equity Incentive Plan remain subject to the approval of the TSX Venture Exchange.
  • For further details regarding the matters approved at the Meeting, please see a copy of the Circular, which is available on the Companys profile at www.sedar.com .
  • Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries.
  • Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned The Joint Commissions Gold Seal of Approval.

NeuroOne® Medical Technologies Corporation Announces First Human Commercial Use of its Evo™ Cortical Electrode at Mayo Clinic

Retrieved on: 
Thursday, December 3, 2020
Branches of biology, Neurophysiology, Mayo Clinic, Electrode, Mayo, Neurotechnology, Electrophysiology, Electrodiagnosis

EDEN PRAIRIE, Minn., Dec. 3, 2020 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today the first human commercial use of its Evo Cortical Electrode at Mayo Clinic in Rochester, Minnesota.

Key Points: 
  • EDEN PRAIRIE, Minn., Dec. 3, 2020 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today the first human commercial use of its Evo Cortical Electrode at Mayo Clinic in Rochester, Minnesota.
  • Three NeuroOne electrodes were also used in addition to fourAd-Tech Medical electrodes during the procedure.
  • Dave Rosa, president and CEO, NeuroOne, says, "After years of development it was exciting to witness the initial validationof our Evo cortical electrode technology at Mayo Clinic.
  • In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015.

Brain Scientific Files Patent Application For New Long-Term Monitoring EEG Cap

Retrieved on: 
Wednesday, December 2, 2020
Branches of biology, Electrophysiology, Neurophysiology, Neurotechnology, Brain–computer interfacing, Electrodiagnosis, Electroencephalography, Seizure, Electrode, Ear-EEG, Pharmaco-electroencephalography

During EEG testing electrodes are put to the persons head by either a cap application or placement of each electrode.

Key Points: 
  • During EEG testing electrodes are put to the persons head by either a cap application or placement of each electrode.
  • Additionally, when an electrode cap is used for EEG, customizing it to fit users remains a challenge due to the various head sizes.
  • The new EEG product for which Brain Scientific is seeking a patent approval is a flexible head cap for conducting electroencephalography.
  • Traditionally, EEG tests have been useful in helping diagnose conditions relating to brain injuries, such as seizures, strokes, brain tumors, Alzheimers disease and certain psychoses.

Assure Holdings Enters Into Commitments To Receive Approximately US$10 Million From Institutional Investors

Retrieved on: 
Monday, November 30, 2020
Medical specialties, Clinical medicine, Medicine, Anesthesia, Electrodiagnosis, Electroencephalography, Intraoperative neurophysiological monitoring, Medical monitoring, Orthopedic surgery

Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price of USD$0.78 for a period of 5 years from the date of issuance.

Key Points: 
  • Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price of USD$0.78 for a period of 5 years from the date of issuance.
  • In connection with the Offering, the Company anticipates paying fees of approximately US$940,000.
  • Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries.
  • Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned The Joint Commissions Gold Seal of Approval.

Assure to Attend Investor Conferences in December 2020

Retrieved on: 
Wednesday, November 25, 2020
Clinical medicine, Electroencephalography, Anesthesia, Electrodiagnosis, Intraoperative neurophysiological monitoring, Medical monitoring, OTC Markets Group, Branches of biology

DENVER, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, announced that management will participate in the following investor conferences in December 2020:

Key Points: 
  • DENVER, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, announced that management will participate in the following investor conferences in December 2020:
    Diamond Equity Research Emerging Growth Invitational on December 1, 2020.
  • Assures executive chairman and CEO John Farlinger is scheduled to present on December 1st at 1:00 p.m.
  • Register for the webcast here: https://us02web.zoom.us/webinar/register/WN_KuHurFdvRh2Y_jOQJe8sYg
    Lytham Partners Virtual Investor Growth Conference on December 7-11, 2020.
  • Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned the Joint Commissions Gold Seal of Approval.

FDA Clears First of its Kind Algorithm Suite for Personal ECG

Retrieved on: 
Monday, November 23, 2020
Medicine, Branches of biology, Medical technology, Cardiac arrhythmia, Alivecor, Cardiac electrophysiology, Electrodiagnosis, Electrocardiography, Premature ventricular contraction, Kardia, Wireless ambulatory ECG

"Kardia AI V2 is the most sophisticated AI ever brought to personal ECG," said AliveCor CEO Priya Abani.

Key Points: 
  • "Kardia AI V2 is the most sophisticated AI ever brought to personal ECG," said AliveCor CEO Priya Abani.
  • This new FDA 510(K) clearance provides detail and fidelity unlike any previously seen in personal ECG devices including:
    A "Sinus Rhythm with Premature Ventricular Contractions (PVCs)" determination if two or more ventricular ectopic beats are detected.
  • The FDA-cleared KardiaMobile device is the most clinically validated personal ECG solution in the world.
  • AliveCor is a privately-held company headquartered in Mountain View, Calif. "Consumer" or "Personal" ECGs are ECG devices available for direct sale to consumers.

The Intraoperative Neuromonitoring Market in the US- Accurate Neuromonitoring LLC, Computational Diagnostics Inc., among others to contribute to the market growth | Industry Analysis, Market Trends, and Forecast 2020-2024

Retrieved on: 
Friday, November 20, 2020
Medical Supplies, Medical devices, Health, Hospitals, Surgery, Other Health, Clinical medicine, Electroencephalography, Anesthesia, Electrodiagnosis, Intraoperative neurophysiological monitoring, Medical monitoring, Branches of biology

The intraoperative neuromonitoring market in the US is poised to grow by USD 955.33 mn during 2020-2024, progressing at a CAGR of over 10% during the forecast period.

Key Points: 
  • The intraoperative neuromonitoring market in the US is poised to grow by USD 955.33 mn during 2020-2024, progressing at a CAGR of over 10% during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20201119006017/en/
    Technavio has announced its latest market research report titled Intraoperative Neuromonitoring Market in US 2020-2024 (Graphic: Business Wire)
    The report on the intraoperative neuromonitoring market in the US provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The intraoperative neuromonitoring market in US analysis includes type segment, application segment, methodology segment, and end-user segment.
  • This study identifies the increasing number of surgeries that require IONM as one of the prime reasons driving the intraoperative neuromonitoring market in the US growth during the next few years.

AliveCor Appoints Toby Cosgrove, M.D. to Board of Directors

Retrieved on: 
Monday, November 9, 2020
Medicine, Medical technology, Branches of biology, Alivecor, Cardiac electrophysiology, Electrodiagnosis, Cosgrove, Electrocardiography, Abani

MOUNTAIN VIEW, Calif., Nov. 9, 2020 /PRNewswire/ -- AliveCor , the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced the appointment of Dr. Toby Cosgrove, to its Board of Directors.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 9, 2020 /PRNewswire/ -- AliveCor , the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced the appointment of Dr. Toby Cosgrove, to its Board of Directors.
  • "I am excited for the opportunity to further AliveCor's mission of making heart care more accessible, affordable, and convenient.
  • "Dr. Cosgrove is an invaluable addition to our Board of Directors and I am incredibly honored to welcome him to theteam," said Priya Abani, CEO of AliveCor.
  • AliveCor is a privately-held company headquartered in Mountain View, Calif. "Consumer" or "Personal" ECGs are ECG devices available for direct sale to consumers.

Assure Reports a Record Number of Monthly Procedures in October 2020

Retrieved on: 
Monday, November 9, 2020
Clinical medicine, Anesthesia, Electrodiagnosis, Electroencephalography, Intraoperative neurophysiological monitoring, Medical monitoring, International Financial Reporting Standards, OTC Markets Group, Branches of biology

DENVER, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), announced its highest ever number of monthly procedures during October 2020.

Key Points: 
  • DENVER, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), announced its highest ever number of monthly procedures during October 2020.
  • The Company reported our highest number of monthly procedures in October, managing nearly 1,000 cases.
  • Farlinger continued, Assure believes it will be a leader in the development of clinical research relating to IONM.
  • This press release includes certain measures which have not been prepared in accordance with International Financial Reporting Standards (IFRS) such as monthly procedures performed.